**Trader consensus against a Trump pardon for Ghislaine Maxwell by the end of 2026 reflects sustained political risks tied to her 2021 sex-trafficking conviction involving minors and Jeffrey Epstein.** As of mid-2026, President Trump has repeatedly stated he has not thought about clemency and would need to consult the Justice Department, without signaling active consideration. Maxwell’s attorney has expressed optimism about a potential deal in exchange for testimony but acknowledged the current Epstein files controversy makes timing unfavorable. Congressional developments have highlighted barriers: House Oversight Committee members remain divided following April 2026 discussions, with Chairman James Comer opposing a pardon-for-testimony arrangement and Democrats unified against it. Acting Attorney General Todd Blanche stated in May he would not recommend clemency. Bipartisan resolutions and survivor advocacy have further underscored the issue’s toxicity, with Maxwell transferred to a lower-security facility in 2025 but showing no clear path to executive relief. These factors, combined with the administration’s focus on containing Epstein-related scrutiny, support the market’s strong “No” pricing.